Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

September 10, 2019 Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …
News

Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US

September 9, 2019 Sales and Marketing Novo Nordisk, NovoLog, insulin

Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price …
News
lilly_entrance_web

Lilly’s LOXO-292 shrinks tumours in lung cancer trial

September 9, 2019 Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma

Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
News
shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019 Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
News
trump-fda

Trump’s FDA: Is the US regulator being steered by the President?

September 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma

FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
Feature
novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019 Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
News

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019 Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 6, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit

It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
News

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019 Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
News
novartis_window

Novartis’ Lucentis secures European approval for infants with rare eye disease

September 6, 2019 Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma

Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
News

Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

September 6, 2019 Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
News
shutterstock_273326141

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019 Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019 Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
News
shutterstock_3

Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals

September 5, 2019 Research and Development, Sales and Marketing Cancer, FDA, US, pharma

The number of cancer drug approvals in the US has surged over the last decade to account for over one …
News
470px-blank_ireland

Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority

September 5, 2019 Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma

Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025